Abstract
Aromatase is the enzyme responsible for the conversion of androgens to estrogens and represents the main source of local estrogens in post-menopausal breast cancer tissue. Nonsteroidal aromatase inhibitors (NSAIs) are able to reduce growth-stimulatory effects of estrogens in hormone-dependent breast cancer, and third generation NSAIs are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic advanced breast cancer. Nevertheless, some issues in this area still need to be addressed and research efforts are aimed both at identifying new molecules of therapeutic interest and at exploring different options for the modulation of this enzyme. In this review, an update of the latest developments in the field of NSAIs is presented, to provide a broad view on the recent progress in this area. Beside classical structure-activity relationships studies and development of natural product derivatives, rational approaches for both ligand- and structure-based design are described. Moreover, novel strategies for the development of multitarget-directed molecules are also presented. Finally, some possible future developments in this research area are briefly considered.
Keywords: Drug discovery, breast cancer, antiestrogen, CYP-450, structure-activity relationships
Current Topics in Medicinal Chemistry
Title: From Nonsteroidal Aromatase Inhibitors to Multifunctional Drug Candidates: Classic and Innovative Strategies for the Treatment of Breast Cancer
Volume: 8 Issue: 10
Author(s): Silvia Gobbi, Andrea Cavalli, Alessandra Bisi and Maurizio Recanatini
Affiliation:
Keywords: Drug discovery, breast cancer, antiestrogen, CYP-450, structure-activity relationships
Abstract: Aromatase is the enzyme responsible for the conversion of androgens to estrogens and represents the main source of local estrogens in post-menopausal breast cancer tissue. Nonsteroidal aromatase inhibitors (NSAIs) are able to reduce growth-stimulatory effects of estrogens in hormone-dependent breast cancer, and third generation NSAIs are currently approved as first-line therapy for the treatment of postmenopausal women with metastatic advanced breast cancer. Nevertheless, some issues in this area still need to be addressed and research efforts are aimed both at identifying new molecules of therapeutic interest and at exploring different options for the modulation of this enzyme. In this review, an update of the latest developments in the field of NSAIs is presented, to provide a broad view on the recent progress in this area. Beside classical structure-activity relationships studies and development of natural product derivatives, rational approaches for both ligand- and structure-based design are described. Moreover, novel strategies for the development of multitarget-directed molecules are also presented. Finally, some possible future developments in this research area are briefly considered.
Export Options
About this article
Cite this article as:
Gobbi Silvia, Cavalli Andrea, Bisi Alessandra and Recanatini Maurizio, From Nonsteroidal Aromatase Inhibitors to Multifunctional Drug Candidates: Classic and Innovative Strategies for the Treatment of Breast Cancer, Current Topics in Medicinal Chemistry 2008; 8 (10) . https://dx.doi.org/10.2174/156802608784911590
DOI https://dx.doi.org/10.2174/156802608784911590 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Natural Products and Colon Drug Delivery ]
Current Drug Delivery CypD: The Key to the Death Door
CNS & Neurological Disorders - Drug Targets Berberine Administration in Treatment of Colitis: A Review
Current Drug Targets Nanoemulsions for Improved Efficacy of Phytotherapeutics- A Patent Perspective
Recent Patents on Nanotechnology The Role of Drug Transporters in the Pharmacokinetics of Antibiotics
Current Drug Metabolism Uptake and Metabolism of the Short-Chain Fatty Acid Butyrate, a Critical Review of the Literature
Current Drug Metabolism The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Relationships Between the Structural Properties of Flavonoids and their Inhibitory Activities Against Matrix Metallopeptidase 9
Letters in Drug Design & Discovery Regulation of Mesenchymal Phenotype by MicroRNAs in Cancer
Current Cancer Drug Targets Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Glucans as Biological Response Modifiers
Endocrine, Metabolic & Immune Disorders - Drug Targets CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Spectroscopic Characterization of a Pyridine Alkaloid from an Endophytic Strain of the Fusarium incarnatum-equiseti Species Complex
Current Bioactive Compounds Characterization of Liver- and Cancer-type-Organic Anion Transporting Polypeptide (OATP) 1B3 Messenger RNA Expression in Normal and Cancerous Human Tissues
Drug Metabolism Letters The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders – A Focus on the Modulation of Host Tissue Function
Mini-Reviews in Medicinal Chemistry Pro- and Anti-Inflammatory Cytokine Expression Levels in Macrophages; An Approach to Develop Indazolpyridin-methanones as Novel Inflammation Medication
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology